Clinical Trial

Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)

Name: Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17) — clinical trial record (NCT03643549)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: BORTEM-17

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This phase IB/II trial is designed to investigate the safety and survival benefits for patients with recurrent grade-4 with unmethylated MGMT promoter treated with Bortezomib and Temozolomide in a specific schedule.

Trial Details

NCT Number	NCT03643549
Lead Sponsor	Haukeland University Hospital Collaborators: Oslo University Hospital, St. Olavs Hospital, University Hospital of North Norway, University of Bergen, University of Bonn, University of Oslo
Conditions	Glioblastoma
Enrollment	63 participants
Start Date	2018-08-30
Primary Completion	2026-12-30 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-04